Brain Health & Advanced Neuroimaging

Yes. A brain MRI is a safe, non-invasive exam that does not use radiation. It uses a magnetic field and radio waves to create detailed images of the brain.

Most scans are completed in approximately 30 minutes. Your care team will share preparation instructions and timing details before your appointment.

Your images are reviewed by contracted radiologists, including specialized neuroradiologists — fellowship-trained physicians who focus on the brain, spine, and head and neck. Results are shared with your provider to guide next steps.

You may benefit from advanced neuroimaging if you experience memory loss or cognitive changes, have a family history of neurological conditions such as Alzheimer’s disease, or have been referred by your physician for further evaluation of other neurologic signs or symptoms.

Advanced neuroimaging can provide insights into memory-related conditions including Alzheimer’s disease, brain atrophy and age-related changes, white matter changes linked to vascular health, and other neurological conditions affecting brain structure and function.

DeepHealth Brain Health and Brain Age, FDA-cleared AI software, automatically measure white matter changes and brain volume on your MRI. They help detect subtle changes over time, compared with your prior exams and normal aging patterns, giving your physician objective measurements to support follow-up care. The exam is reviewed and interpreted by fellowship-trained neuroradiologists.

Most advanced neuroimaging exams are ordered by your physician. Coverage varies by exam, medical history, and insurance plan — our teams can help review coverage questions and scheduling requirements before your visit.

Yes. Confirmation of the presence of beta-amyloid plaque in the brain is required prior to starting medication. This may be done with a lumbar puncture, but a PET scan is also reliable for detecting this toxic protein in the brain and far more comfortable for patients. A baseline MRI is also required before starting anti-amyloid therapy, with follow-up MRIs at set points in the first months of treatment and if symptoms appear. Only patients with mild cognitive impairment (MCI) or early Alzheimer’s are eligible for the use of anti-amyloid therapy.

PET/MRI is an efficient tool that combines required screening protocols into one convenient exam. For patients considering anti-amyloid therapy it can simultaneously provide the required brain MRI for treatment eligibility and the required biomarker for beta-amyloid pathology, with a reduced radiation dose. Amyloid PET/MRI is now covered by Medicare for patients receiving anti-amyloid therapy.